Medtronic plc. Company Profile (NYSE:MDT)

About Medtronic plc. (NYSE:MDT)

Medtronic plc. logoMedtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:MDT
  • CUSIP: 58505510
  • Web:
  • Market Cap: $116.48 billion
  • Outstanding Shares: 1,368,885,000
Average Prices:
  • 50 Day Moving Avg: $82.53
  • 200 Day Moving Avg: $78.56
  • 52 Week Range: $69.35 - $89.27
  • Trailing P/E Ratio: 30.04
  • Foreward P/E Ratio: 15.64
  • P/E Growth: 2.34
Sales & Book Value:
  • Annual Revenue: $29.36 billion
  • Price / Sales: 3.97
  • Book Value: $36.08 per share
  • Price / Book: 2.36
  • Annual Dividend: $1.72
  • Dividend Yield: 2.0%
  • EBIDTA: $9.09 billion
  • Net Margins: 14.63%
  • Return on Equity: 12.36%
  • Return on Assets: 6.31%
  • Debt-to-Equity Ratio: 0.58%
  • Current Ratio: 2.35%
  • Quick Ratio: 1.96%
  • Average Volume: 4.23 million shs.
  • Beta: 0.97
  • Short Ratio: 2.29

Frequently Asked Questions for Medtronic plc. (NYSE:MDT)

What is Medtronic plc.'s stock symbol?

Medtronic plc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic plc. pay dividends? What is the dividend yield for Medtronic plc.?

Medtronic plc. declared a quarterly dividend on Friday, March 10th. Investors of record on Friday, March 24th will be given a dividend of $0.43 per share on Thursday, April 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 2.02%. The ex-dividend date of this dividend is Wednesday, March 22nd. View Medtronic plc.'s Dividend History.

How were Medtronic plc.'s earnings last quarter?

Medtronic plc. (NYSE:MDT) issued its quarterly earnings results on Thursday, May, 25th. The company reported $1.33 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.31 by $0.02. The company had revenue of $7.92 billion for the quarter, compared to the consensus estimate of $7.86 billion. Medtronic plc. had a net margin of 14.63% and a return on equity of 12.36%. The business's revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.27 EPS. View Medtronic plc.'s Earnings History.

Where is Medtronic plc.'s stock going? Where will Medtronic plc.'s stock price be in 2017?

26 brokerages have issued 12-month price targets for Medtronic plc.'s stock. Their forecasts range from $77.00 to $102.00. On average, they expect Medtronic plc.'s stock price to reach $87.80 in the next twelve months. View Analyst Ratings for Medtronic plc..

What are analysts saying about Medtronic plc. stock?

Here are some recent quotes from research analysts about Medtronic plc. stock:

  • 1. Needham & Company LLC analysts commented, "F4Q17 revenue and EPS beat consensus and initial FY18 guidance was in line with consensus. Organic revenue growth was steady at 4.0% vs. 4.1% in F3Q17 with new products adding ~370 bps, emerging markets adding ~125 bps and services & solutions adding ~15 bps. Operating margin was above consensus and up 10 bps Y/Y (or 40 bps Y/Y CC). MDT’s product cycle remains strong with significant FY18 launches including: the Resolute Onyx DES, MiniMed 670G insulin pump, Signia powered stapler, new LigaSure instruments, Intellis spinal cord stimulator, Evolut PRO TAVR, and MRI CRT-P quadripolar system." (5/25/2017)
  • 2. According to Zacks Investment Research, "Ahead of its fourth quarter fiscal 2017 result, we believe Medtronic will do well banking on strong performances of major business groups with sustainability across all regions. Earlier, the company observed solid growth trend in the U.S. on healthy global acceptance of its therapies. Particularly, we are optimistic about the gradually stabilizing trend in the global CRHF market. This yet-to-be-reported quarter is expected to be no exception to that. The company is currently on a spree of gaining regulatory approvals for its minimally invasive devices which is quite encouraging. On the flip side, escalating costs and expenses weighing on margins is a concern. Also, unfavorable foreign exchange continues to remain a drag. A dull fiscal guidance fails to indicate any chances of respite soon. This has been reflected in the company’s share price trend too. In the past one month, Medtronic consistently traded below the Zacks categorized Medical Product industry." (5/23/2017)
  • 3. BTIG Research analysts commented, "At last Friday's American College of Cardiology (ACC) meeting, two-year data on MDT's SURTAVI trial for intermediate-risk was presented. At the two-year mark, all cause death/stroke were similar for TAVR using MDT's valves (12.6%) vs. surgery (14%) though use of TAVR reduced 30-day strokes, kidney injury, afib, and hospital stay. While we were surprised TAVR was not superior to surgery as in other trials, it seems surgical results improved. Still, TAVR is at least as good with less invasiveness. While not the same trials, investors have tried to compare MDT's CoreValve to Edwards' (EW, Neutral) SAPIEN 3 based on available data. At 1 year, all-cause death and stroke were equivalent at 8.1% for CoreValve and 8.4% for SAPIEN 3. Overall, patient selection (EW's intermediate risk pool may have had more comorbidities) and device design (MDT mainly used its older valve) make it tough to directly compare both trials; but we believe the valves are essentially equivalent and either one should be chosen over surgery." (3/20/2017)
  • 4. Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)
  • 5. Evercore ISI analysts commented, "MDT started 2017 with a solid execution, highlighted by all around revenue beat and operating margins that were generally in line with ST (came in above us). The importance of this Q cannot be underestimated in our mind, as sentiment had turned negative (post a disappointing 1H) and the stock multiple (3-6x discount to peer group) was see-sawing precariously at ~15-16x P/E. While the bar had been lowered, MDT needed to deliver to flawless Q to instill investor confidence and start the path towards multiple correction (vs. group). The company began its first step, highlighted by a solid revenue beat, driven by high single digit growth in CR&HF. This is a key segment, and the ~8% growth should provide comfort against the bear thesis of competitive share losses / replacement cycle headwinds. We were also encouraged to see ~30% growth in TAVR, and a full rollout of the 34mm valve (launched only in 50% of centers) plus Intermediate Risk approval in early 2018 bodes well. Other key drivers in 2018 include the full commercial launch of 670G in Diabetes, Resolute Onyx launch, continued growth in AF, Link, DCBs, and the continued turnaround in Spine provides incremental confidence in MDT being able to sustain ~4% organic topline in the medium term. The second leg of value creation will rest on margin expansion, with the ST still skeptical of the company's ability to show margin expansion on a reported basis (including the impact of Fx hedges). We believe that the margin expansion thesis will play out in 2018, and will play a huge role in MDT's ability to close its P/E gap vs. peer group average. We expect this combination of a potential multiple reflation trade along with upside from capital deployment (incremental ~$3 Bn could potentially be accessible in near term post IRS settlement) to drive value for investors over the next 12 months." (2/21/2017)

Who are some of Medtronic plc.'s key competitors?

Who owns Medtronic plc. stock?

Medtronic plc.'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.47%), BlackRock Inc. (6.36%), Wellington Management Group LLP (5.00%), State Street Corp (4.61%), Massachusetts Financial Services Co. MA (4.28%) and FMR LLC (4.17%). Company insiders that own Medtronic plc. stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic plc..

Who sold Medtronic plc. stock? Who is selling Medtronic plc. stock?

Medtronic plc.'s stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, FMR LLC, Primecap Management Co. CA, Manning & Napier Advisors LLC, State Street Corp, Ameriprise Financial Inc., TIAA CREF Investment Management LLC and Schroder Investment Management Group. Company insiders that have sold Medtronic plc. stock in the last year include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, Kendall J Powell, Omar Ishrak, Richard Kuntz and Shirley A Jackson. View Insider Buying and Selling for Medtronic plc..

Who bought Medtronic plc. stock? Who is buying Medtronic plc. stock?

Medtronic plc.'s stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Lazard Asset Management LLC, Vanguard Group Inc., Wells Fargo & Company MN, Massachusetts Financial Services Co. MA, Swiss National Bank, Canada Pension Plan Investment Board and Geode Capital Management LLC. Company insiders that have bought Medtronic plc. stock in the last two years include James T Lenehan and Robert C Pozen. View Insider Buying and Selling for Medtronic plc..

How do I buy Medtronic plc. stock?

Shares of Medtronic plc. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Medtronic plc. stock cost?

One share of Medtronic plc. stock can currently be purchased for approximately $85.09.

Analyst Ratings

Consensus Ratings for Medtronic plc. (NYSE:MDT) (?)
Ratings Breakdown: 10 Hold Ratings, 16 Buy Ratings
Consensus Rating:Buy (Score: 2.62)
Consensus Price Target: $87.80 (3.18% upside)

Analysts' Ratings History for Medtronic plc. (NYSE:MDT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/26/2017CIBCReiterated RatingBuyLowView Rating Details
5/25/2017Needham & Company LLCReiterated RatingBuy -> Buy$91.00 -> $95.00LowView Rating Details
5/25/2017Oppenheimer Holdings Inc.Reiterated RatingBuy$93.00LowView Rating Details
5/16/2017Goldman Sachs Group IncInitiated CoverageNeutral -> Neutral$87.00LowView Rating Details
4/20/2017Northland SecuritiesReiterated RatingHold$80.00MediumView Rating Details
4/19/2017Evercore ISIBoost Price TargetOutperform$88.00 -> $88.50MediumView Rating Details
4/18/2017Royal Bank of CanadaReiterated RatingBuy$85.00LowView Rating Details
3/20/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
2/23/2017Leerink SwannBoost Price TargetMarket Perform$80.00 -> $85.00N/AView Rating Details
2/22/2017WedbushReiterated RatingNeutral$85.00N/AView Rating Details
2/17/2017Jefferies Group LLCReiterated RatingBuy$88.00N/AView Rating Details
1/8/2017Deutsche Bank AGSet Price TargetBuy$96.00N/AView Rating Details
1/3/2017Morgan StanleyReiterated RatingEqual Weight -> OverweightN/AView Rating Details
1/3/2017Bank of America CorpDowngradeBuy -> Neutral$78.00N/AView Rating Details
1/3/2017JPMorgan Chase & Co.DowngradeOverweight -> Neutral$84.00 -> $79.00N/AView Rating Details
11/23/2016Barclays PLCLower Price TargetOverweight$93.00 -> $85.00N/AView Rating Details
11/23/2016BMO Capital MarketsLower Price TargetOutperform$94.00 -> $87.00N/AView Rating Details
11/23/2016Stifel NicolausLower Price TargetHold$91.00 -> $81.00N/AView Rating Details
8/25/2016Credit Suisse Group AGReiterated RatingOutperform$92.00N/AView Rating Details
8/23/2016Cowen and CompanySet Price TargetBuy$94.00N/AView Rating Details
8/23/2016Citigroup IncInitiated CoverageBuy$63.98 -> $102.00N/AView Rating Details
6/20/2016ArgusReiterated RatingHold -> HoldN/AView Rating Details
6/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$93.00 -> $94.00N/AView Rating Details
6/13/2016SunTrust Banks, Inc.Boost Price TargetBuy$93.00 -> $98.00N/AView Rating Details
6/8/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
6/7/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$86.00N/AView Rating Details
9/4/2015William BlairReiterated RatingOutperformN/AView Rating Details
6/25/2015Sterne Agee CRTReiterated RatingNeutralN/AView Rating Details
6/4/2015S&P Equity ResearchReiterated RatingBuy$89.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Medtronic plc. (NYSE:MDT)
Earnings by Quarter for Medtronic plc. (NYSE:MDT)
Earnings History by Quarter for Medtronic plc. (NYSE:MDT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/25/2017Q4 17$1.31$1.33$7.86 billion$7.92 billionViewN/AView Earnings Details
2/21/20171/31/2017$1.11$1.12$7.22 billion$7.28 billionViewListenView Earnings Details
11/22/2016Q217$1.11$1.12$7.46 billion$7.35 billionViewListenView Earnings Details
8/25/2016Q117$1.01$1.03$7.17 billion$7.20 billionViewListenView Earnings Details
5/31/2016Q416$1.26$1.27$7.49 billion$7.57 billionViewListenView Earnings Details
3/1/2016Q316$1.06$1.06$6.99 billion$6.93 billionViewListenView Earnings Details
12/3/2015Q216$1.00$1.03$7.08 billion$7.06 billionViewListenView Earnings Details
9/3/2015Q116$1.01$1.02$7.03 billion$7.27 billionViewListenView Earnings Details
6/2/2015Q415$1.11$1.16$7.18 billion$7.30 billionViewListenView Earnings Details
2/17/2015Q3$0.97$1.01$4.25 million$4.32 millionViewListenView Earnings Details
11/18/2014Q2$0.96$0.96$4.37 million$4.40 millionViewListenView Earnings Details
8/19/2014Q115$0.92$0.93$4.25 billion$4.27 billionViewListenView Earnings Details
5/20/2014Q414$1.12$1.12$4.58 billion$4.60 billionViewListenView Earnings Details
2/18/2014Q314$0.91$0.91$4.15 billion$4.20 billionViewListenView Earnings Details
11/19/2013Q214$0.90$0.91$4.18 billion$4.20 billionViewListenView Earnings Details
8/20/2013Q1 2014$0.88$0.88$4.11 billion$4.10 billionViewListenView Earnings Details
5/21/2013Q4 2013$1.03$1.10$4.39 billion$4.50 billionViewListenView Earnings Details
2/19/2013Q3 2013$0.91$0.93$4.03 billion$4.03 billionViewListenView Earnings Details
11/20/20120.88$0.88$4.10 billionViewN/AView Earnings Details
8/21/2012$0.85$0.85ViewN/AView Earnings Details
5/22/2012$0.98$0.99ViewN/AView Earnings Details
2/21/2012$0.84$0.88ViewN/AView Earnings Details
11/22/2011$0.82$0.84ViewN/AView Earnings Details
8/23/2011$0.79$0.79ViewN/AView Earnings Details
5/24/2011$0.93$0.90ViewN/AView Earnings Details
2/22/2011$0.84$0.86ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Medtronic plc. (NYSE:MDT)
2017 EPS Consensus Estimate: $4.62
2018 EPS Consensus Estimate: $4.92
2019 EPS Consensus Estimate: $5.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20177$1.00$1.15$1.03
Q2 20177$1.10$1.37$1.16
Q3 20177$1.10$1.15$1.12
Q4 20177$1.29$1.34$1.31
Q1 20186$1.07$1.15$1.11
Q2 20186$1.15$1.20$1.18
Q3 20186$1.17$1.27$1.22
Q4 20186$1.35$1.46$1.41
Q1 20191$1.20$1.20$1.20
Q2 20191$1.26$1.26$1.26
Q3 20191$1.36$1.36$1.36
Q4 20191$1.56$1.56$1.56
(Data provided by Zacks Investment Research)


Current Dividend Information for Medtronic plc. (NYSE:MDT)
Most Recent Dividend:4/13/2017
Annual Dividend:$1.72
Dividend Yield:2.02%
Dividend Growth:25.50% (3 Year Average)
Payout Ratio:57.14% (Trailing 12 Months of Earnings)
34.68% (Based on This Year's Estimates)
31.62% (Based on Next Year's Estimates)
Track Record:39 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Medtronic plc. (NYSE:MDT)

Dividend History by Quarter for Medtronic plc. (NYSE:MDT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Medtronic plc. (NYSE:MDT)
Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 82.71%
Insider Trades by Quarter for Medtronic plc. (NYSE:MDT)
Institutional Ownership by Quarter for Medtronic plc. (NYSE:MDT)
Insider Trades by Quarter for Medtronic plc. (NYSE:MDT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Hoedt Rob TenEVPSell50,757$81.58$4,140,756.06View SEC Filing  
3/15/2017Omar IshrakCEOSell95,000$82.82$7,867,900.00View SEC Filing  
3/2/2017Hooman HakamiEVPSell52,316$82.33$4,307,176.28View SEC Filing  
12/13/2016Robert C. PozenDirectorBuy13,660$73.21$1,000,048.60View SEC Filing  
11/23/2016James T. LenehanDirectorBuy2,000$73.27$146,540.00View SEC Filing  
9/27/2016Richard KuntzVPSell17,141$86.70$1,486,124.70View SEC Filing  
9/26/2016Richard KuntzVPSell25,199$86.67$2,183,997.33View SEC Filing  
9/15/2016Kendall J. PowellDirectorSell7,907$85.45$675,653.15View SEC Filing  
9/15/2016Omar IshrakCEOSell61,925$84.93$5,259,290.25View SEC Filing  
8/29/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/26/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/15/2016Geoffrey MarthaEVPSell3,766$88.26$332,387.16View SEC Filing  
7/13/2016Gary Lee EllisEVPSell35,495$88.64$3,146,276.80View SEC Filing  
7/13/2016Shirley A JacksonDirectorSell2,104$88.64$186,498.56View SEC Filing  
7/6/2016Carol A. SurfaceSVPSell9,787$87.08$852,251.96View SEC Filing  
7/5/2016Bryan C. HansonEVPSell15,272$87.11$1,330,343.92View SEC Filing  
6/3/2016Richard KuntzVPSell49,905$82.60$4,122,153.00View SEC Filing  
4/1/2016Richard KuntzVPSell4,000$75.22$300,880.00View SEC Filing  
3/18/2016Shirley A JacksonDirectorSell1,238$75.60$93,592.80View SEC Filing  
3/17/2016Omar IshrakCEOSell23,799$76.15$1,812,293.85View SEC Filing  
3/4/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
2/5/2016Bryan C. HansonEVPSell5,000$76.14$380,700.00View SEC Filing  
1/8/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
12/4/2015Richard KuntzVPSell13,715$78.06$1,070,592.90View SEC Filing  
9/15/2015Omar IshrakCEOSell20,000$69.43$1,388,600.00View SEC Filing  
7/14/2015Carol A SurfaceSVPSell13,722$75.83$1,040,539.26View SEC Filing  
4/6/2015Richard KuntzVPSell31,768$77.39$2,458,525.52View SEC Filing  
3/25/2015Gary Lee EllisCFOSell43,183$77.81$3,360,069.23View SEC Filing  
3/13/2015Omar IshrakCEOSell20,000$76.24$1,524,800.00View SEC Filing  
2/19/2015Christopher J OconnellEVPSell50,361$78.22$3,939,237.42View SEC Filing  
12/19/2014Richard KuntzVPSell12,855$74.54$958,211.70View SEC Filing  
12/2/2014Shirley A JacksonDirectorSell1,102$74.43$82,021.86View SEC Filing  
11/28/2014Christopher J OconnellEVPSell42,921$73.95$3,174,007.95View SEC Filing  
10/6/2014Christopher J OconnellEVPSell15,388$64.98$999,912.24View SEC Filing  
8/26/2014Christopher J OconnellEVPSell28,000$63.57$1,779,960.00View SEC Filing  
8/26/2014Shirley A JacksonDirectorSell2,769$63.66$176,274.54View SEC Filing  
4/17/2014Catherine SzymanVPSell29,420$58.79$1,729,601.80View SEC Filing  
4/9/2014Richard KuntzVPSell2,512$60.98$153,181.76View SEC Filing  
4/1/2014Gary Lee EllisCFOSell4,246$61.48$261,044.08View SEC Filing  
3/28/2014Christopher OconnellEVPSell1,982$60.39$119,692.98View SEC Filing  
3/20/2014Catherine SzymanVPSell14,979$59.57$892,299.03View SEC Filing  
3/14/2014Omar IshrakCEOSell10,000$59.12$591,200.00View SEC Filing  
3/10/2014Neil AyotteVPSell1,845$59.64$110,035.80View SEC Filing  
12/4/2013Neil AyotteVPSell1,729$57.14$98,795.06View SEC Filing  
9/13/2013Omar IshrakCEOSell10,000$53.58$535,800.00View SEC Filing  
8/26/2013Catherine SzymanVPSell56,998$52.60$2,998,094.80View SEC Filing  
8/22/2013H James DallasVPSell32,332$53.19$1,719,739.08View SEC Filing  
8/21/2013H James DallasVPSell36,256$52.82$1,915,041.92View SEC Filing  
8/21/2013Shirley JacksonDirectorSell8,033$52.84$424,463.72View SEC Filing  
7/11/2013Christopher J OconnellEVPSell30,429$52.92$1,610,302.68View SEC Filing  
7/11/2013Gary Lee EllisCFOSell32,602$53.62$1,748,119.24View SEC Filing  
7/11/2013H James DallasVPSell69,889$53.72$3,754,437.08View SEC Filing  
7/1/2013H James DallasVPSell20,579$52.10$1,072,165.90View SEC Filing  
6/26/2013D Cameron FindlayVPSell75,042$52.20$3,917,192.40View SEC Filing  
6/19/2013H James DallasVPSell94,117$52.74$4,963,730.58View SEC Filing  
5/22/2013Richard H AndersonDirectorBuy4,800$52.32$251,136.00View SEC Filing  
5/10/2013Jack W SchulerDirectorSell34,230$48.24$1,651,255.20View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Medtronic plc. (NYSE:MDT)
Latest Headlines for Medtronic plc. (NYSE:MDT)
DateHeadline logoSeptember 2018 Options Now Available For Medtronic (MDT) - May 26 at 7:19 PM logoHow Medtronic Makes Money (MDT) - May 26 at 7:19 PM logoMedtronic plc. (MDT) Stock Rating Reaffirmed by CIBC - May 26 at 5:20 PM logoSunTrust Banks Comments on Medtronic plc.'s Q1 2018 Earnings (MDT) - May 26 at 10:11 AM logoMedtronic's Edwards-Rivaling Unit Outgrows Broader Market In Q4 - May 26 at 3:55 AM logoMedtronic's Spine division shows growth - May 26 at 3:55 AM logoEdited Transcript of MDT earnings conference call or presentation 25-May-17 12:00pm GMT - May 26 at 3:55 AM logoMedtronic plc.'s (MDT) "Buy" Rating Reiterated at Oppenheimer Holdings Inc. - May 25 at 7:58 PM logoMedtronic plc. (MDT) Given "Buy" Rating at Needham & Company LLC - May 25 at 6:04 PM logoJefferies Group Research Analysts Lower Earnings Estimates for Medtronic plc. (MDT) - May 25 at 11:18 AM logoMedtronic plc. (MDT) Releases Earnings Results, Beats Expectations By $0.02 EPS - May 25 at 9:28 AM logoMedtronic (MDT) Enrolls First Patient in Study of IN.PACT AV Access Drug-Coated Balloon in Patients with ESRD - May 24 at 6:31 PM logoMedtronic Chairman and CEO Omar Ishrak to Speak at Goldman Sachs Global Healthcare Conference - May 24 at 6:31 PM logoMedtronic Enrolls First Patient in Study of IN.PACT(TM) AV Access Drug-Coated Balloon in Patients with End-Stage Renal Disease - May 24 at 6:31 PM logoA Look at Medtronic’s Recent Stock Performance - May 24 at 10:51 AM logoMedtronic plc. (MDT) Receives Consensus Recommendation of "Hold" from Brokerages - May 23 at 6:08 PM logoMedtronic plc. (MDT) Downgraded to "Sell" at Zacks Investment Research - May 23 at 1:50 PM logo[$$] Companies Are Winning the Battle Over Adjusted Earnings - May 23 at 10:34 AM logoMedtronic’s Fiscal 4Q17 Results: What Can Investors Expect? - May 23 at 10:34 AM logoMedtronic (MDT) Q4 Earnings: Stock Likely to Beat Again? - May 23 at 10:34 AM logoCompanies Are Winning the Battle Over Adjusted Earnings - May 22 at 10:12 AM logo[$$] Companies Winning the Battle Over Adjusted Earnings - May 22 at 10:12 AM logoMedtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint - May 19 at 11:01 AM logoAmerican Health Council Names Jeffrey Scifert, PhD to Industry Board - May 18 at 11:43 AM logoMedtronic (MDT) Reports RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint - - May 18 at 8:36 AM logoMedtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year - May 18 at 8:36 AM logoMedtronic Study Finds High Use of App-Based Remote Cardiac Monitoring Among Older Patients - May 17 at 6:26 PM logoMedtronic plc. (MDT) Receives New Coverage from Analysts at Goldman Sachs Group Inc - May 16 at 8:56 PM logoMedtronic Stock Falls Following 'Neutral' Goldman Sachs Initiation - May 16 at 6:17 PM logoMedtronic EVP & President Bryan Hanson to Speak at Jefferies 2017 Global Healthcare Conference - May 16 at 6:17 PM logoSome Silicon Valley techies obsessively track their blood sugar -- and they don't have diabetes - May 16 at 10:34 AM logoNew Data on CoreValve(TM) and Evolut(TM) R Self-Expanding TAVI Systems Show Excellent Clinical Outcomes in Routine Clinical Practice - May 16 at 10:34 AM logoWill Wearable Technology Make Us Healthier? - May 16 at 9:10 AM logoData Reinforce Benefits of Medtronic Cardiac Resynchronization Therapy Technologies in 'Real-World' Setting - May 15 at 5:52 PM logoMedtronic (MDT) Says New Study Shows Insertable Cardiac Monitors Detect High Rate of Atrial Fibrillation in Previously Undiagnosed High-Risk Patients - May 12 at 7:07 PM logoNew Medtronic Study Reinforces Safety and Performance of the World's Smallest Pacemaker in a Real-World Patient Population - May 11 at 7:00 PM logoMedtronic Chairman and CEO Omar Ishrak to Speak at Bernstein Strategic Decisions Conference - May 11 at 7:00 PM logoJeff Auxier Comments on Medtronic plc - May 10 at 6:08 PM logoMedtronic (MDT) Receives FDA Approval for MR-Conditional Quadripolar Cardiac Resynchronization Therapy-Pacemakers - May 10 at 12:35 PM logoMedtronic First to Receive FDA Approval for MR-Conditional Quadripolar Cardiac Resynchronization Therapy-Pacemakers - May 10 at 12:35 PM logoMedtronic plc: Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2017 - May 9 at 6:10 PM logoMedtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2017 - May 9 at 6:10 PM logo$7.85 Billion in Sales Expected for Medtronic plc. (MDT) This Quarter - May 6 at 9:52 AM logoOp-Ed: Here’s the real loser in the GOP health-care reform plan - May 5 at 9:50 AM logoMedtronic plc. (MDT) Earning Somewhat Favorable Press Coverage, Analysis Shows - May 4 at 10:02 PM logoSaudi Arabia Woos U.S. Investors for Its Health Care Services - May 4 at 6:35 PM logo$1.31 Earnings Per Share Expected for Medtronic plc. (MDT) This Quarter - May 4 at 7:50 AM logoTraders Buy High Volume of Medtronic plc. Put Options (MDT) - May 3 at 7:06 AM logoSomewhat Favorable Press Coverage Likely to Impact Medtronic plc. (MDT) Stock Price - May 1 at 7:58 PM logoMedtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes - May 1 at 12:41 PM



Medtronic plc. (MDT) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff